09.17.14


Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM

 

Charles J. Vaske1,†, Stephen C. Benz2,†, J. Zachary Sanborn2, Dent Earl2, Christopher Szeto2, Jingchun Zhu2, David Haussler1,2 and Joshua M. Stuart2,*

+ Author Affiliations

1 Howard Hughes Medical Institute and 2 Department of Biomolecular Engineering and Center for Biomolecular Science and Engineering, UC Santa Cruz, CA, USA

* To whom correspondence should be addressed.

Abstract

Motivation: High-throughput data is providing a comprehensive view of the molecular changes in cancer tissues. New technologies allow for the simultaneous genome-wide assay of the state of genome copy number variation, gene expression, DNA methylation and epigenetics of tumor samples and cancer cell lines.

Analyses of current data sets find that genetic alterations between patients can differ but often involve common pathways. It is therefore critical to identify relevant pathways involved in cancer progression and detect how they are altered in different patients.

Results: We present a novel method for inferring patient-specific genetic activities incorporating curated pathway interactions among genes. A gene is modeled by a factor graph as a set of interconnected variables encoding the expression and known activity of a gene and its products, allowing the incorporation of many types of omic data as evidence. The method predicts the degree to which a pathway’s activities (e.g. internal gene states, interactions or high-level ‘outputs’) are altered in the patient using probabilistic inference.

Compared with a competing pathway activity inference approach called SPIA, our method identifies altered activities in cancer-related pathways with fewer false-positives in both a glioblastoma multiform (GBM) and a breast cancer dataset. PARADIGM identified consistent pathway-level activities for subsets of the GBM patients that are overlooked when genes are considered in isolation. Further, grouping GBM patients based on their significant pathway perturbations divides them into clinically-relevant subgroups having significantly different survival outcomes. These findings suggest that therapeutics might be chosen that target genes at critical points in the commonly perturbed pathway(s) of a group of patients.

Availability:Source code available at http://sbenz.github.com/Paradigm

Contact: jstuart@soe.ucsc.edu

Supplementary information: Supplementary data are available at Bioinformatics online.

Leave a comment

Your email address will not be published. Required fields are marked *

Time limit is exhausted. Please reload CAPTCHA.